iMedi.co.uk

Bob Martin Clear Flea 57mg Tablets For Large Dogs

Revised: June 2016

AN: 00240/2016


SUMMARY OF PRODUCT CHARACTERISTICS


NAME OF THE VETERINARY MEDICINAL PRODUCT


Bob Martin Clear Flea 57mg Tablets For Large Dogs


QUALITATIVE AND QUANTITATIVE COMPOSITION


One tablet contains:


Active substance:

Nitenpyram 57 mg


Excipients:

For a full list of excipients, see section 6.1.


PHARMACEUTICAL FORM


Tablet.

White to light yellow, round, biconvex tablets, with bevelled edges, imprinted on one side with “HIH”, on the other side with “CG”.


CLINICAL PARTICULARS


Target species


Dog


Indications for use, specifying the target species


Treatment of flea infestations (C. felis) on dogs.


Contraindications


None.


Special warnings for each target species


None.


Special precautions for use


Special precautions for use in animals


Do not use on dogs weighing less than 11 kg.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


None.


Adverse reactions (frequency and seriousness)


For the first hour after administration, the pet may scratch more than normal. This effect is caused by the fleas reacting to the product.


Use during pregnancy, lactation or lay


Nitenpyram can be used during pregnancy and lactation. Studies in laboratory animals (rats and rabbits) have produced no evidence of teratogenic or foetotoxic effects and the safety of the product was demonstrated in pregnant and lactating cats and dogs.


Interaction with other medicinal products and other forms of interaction


None known. No adverse drug reactions were seen in clinical studies when nitenpyram was administered with other veterinary medicinal products including commonly used flea products, anthelmintics, vaccines or antibiotics.


Amounts to be administered and administration route


The minimum effective recommended dose is 1 mg/kg, with the following recommendations:


One Bob Martin Clear Flea 57mg tablet should be given to dogs weighing 11.1 kg to 57.0 kg and two tablets for dogs weighing over 57 kg when a flea infestation is detected. The frequency of treatment depends on the degree of infestation. In the case of a severe flea infestation, it may be necessary to treat the animals every day or every other day, until the flea infestation is controlled. Treatment may be resumed if fleas reappear. No more than one treatment should be given per day.


Tablets should be given orally, with or without food. In order to improve palatability, tablets can be disguised in a small quantity of food immediately prior to administration.


Bob Martin Clear Flea 57mg Tablets does not have persistent activity. To prevent re-infestation, a suitable treatment to control immature stages of the flea life cycle is recommended. The veterinary surgeon should establish an appropriate treatment regime.


Overdose (symptoms, emergency procedures, antidotes), if necessary


Nitenpyram is well-tolerated by the target species. Overdoses up to 50 mg/kg in cats and up to 70 mg/kg in dogs were asymptomatic.


Side-effects such as salivation, vomiting, soft stools, seizures, or decreased activity are observed at higher dosages and their seriousness increases as dosages increase. Symptoms disappear quickly and recovery is complete by 24 hours after overdosing because of the rapid elimination of nitenpyram. During 6 months of daily dosing in cats and dogs no clinically significant treatment-related side effects were observed.

Withdrawal period


Not applicable.


PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group:Other ectoparasiticides for systemic use, ATCvet code:QP53BX02.


Pharmacodynamic properties


The active ingredient, nitenpyram belongs to the chemical class of neonicotinoids which bind and inhibit insect specific nicotinic acetylcholine receptors. Nitenpyram interferes with nerve transmission and leads to the death of adult fleas. Nitenpyram does not inhibit acetylcholinesterase.


Effects on fleas (Ctenocephalides felis) may be seen as soon as 15-30 minutes after administration of the product to the host animal. This coincides with the first blood meal taken by fleas after sufficient blood levels are reached. Between 95% and 100% efficacy is observed within the first 6 hours and 100% efficacy is reached within 24 hours with no residual activity.


Pharmacokinetic particular


Nitenpyram is rapidly and to over 90% absorbed from the gastrointestinal tract of cats and dogs. Feeding does not affect absorption in dogs. Feeding slightly delays Tmax in cats without affecting the other pharmacokinetic properties and without affecting efficacy. The maximum blood concentration is reached after 0.5 to 2 hours in both fasted target species and the elimination half-life is about 4 hours in dogs and 8 hours in cats. More than 90% is eliminated in the urine within 1 day in dogs and 2 days in cats, mainly as the unchanged molecule.


PHARMACEUTICAL PARTICULARS


List of excipients


Microcrystalline cellulose

Maize starch

Lactose monohydrate

Silica, colloidal anhydrous

Magnesium stearate


Incompatibilities


Not applicable.


Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 3 years.


Special precautions for storage


Do not store above 25C.


Nature and composition of immediate packaging


Cardboard box with 1 or 10 polyamide/aluminium/PVC-aluminium blisters. Each blister contains 3 tablets.

Cardboard box with 1or 10 polyamide/aluminium/PVC-aluminium blisters. Each blister contains 6 tablets.

Not all pack sizes may be marketed.


Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Any unused veterinary medicinal product or waste material derived from the use of veterinary medicinal products should be disposed of in accordance with local requirements.


MARKETING AUTHORISATION HOLDER


Elanco Europe Ltd

Lilly House

Priestley Road

Basingstoke

Hampshire

RG24 9NL


MARKETING AUTHORISATION NUMBER


Vm 00879/4059


DATE OF FIRST AUTHORISATION


12 January 2009


DATE OF REVISION OF THE TEXT


June 2016


Approved: 21 June 2016

Page 4 of 4